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Joubert syndrome (JBts) is an incurable multisystem ciliopathy syndrome. the most commonly 
mutated gene in JBts patients with a cerebello-retinal-renal phenotype is CEP290 (alias JBTS5). the 
encoded CEP290 protein localises to the proximal end of the primary cilium, in the transition zone, 
where it controls ciliary protein composition and signalling. We examined primary cilium structure 
and composition in fibroblast cells derived from homozygous and compound heterozygous JBTS5 
patients with nonsense mutations in CEP290 and show that elongation of cilia, impaired ciliogenesis 
and ciliary composition defects are typical features in JBTS5 cells. Targeted skipping of the mutated 
exon c.5668 G > T using antisense oligonucleotide (ASO) therapy leads to restoration of CEP290 protein 
expression and functions at the transition zone in homozygous and compound heterozygous JBTS5 
cells, allowing a rescue of both cilia morphology and ciliary composition. this study, by demonstrating 
that targeted exon skipping is able to rescue ciliary protein composition defects, provides functional 
evidence for the efficacy of this approach in the treatment of JBTS.
Joubert Syndrome (JBTS) is an incurable multisystem condition, in most cases inherited as an autosomal reces-
sive disease. The diagnostic hallmark of JBTS patients is a characteristic cerebellar malformation, known as the 
‘molar tooth sign’, which is accompanied by hypotonia, ataxia, oculo-motor apraxia, global developmental delay 
and breathing dysregulation. Such neurological defects can variably be associated with multi-organ involvement 
leading to retinal degeneration, renal and liver disease.
To date, more than 30 genes have been associated with JBTS, all of which encode for proteins that are impli-
cated in ciliary structure, assembly and/or function. Primary cilia are non-motile microtubule-based specialized 
organelles that protrude from the surface of many quiescent or post-mitotic eukaryotic cells. The primary cilium 
acts as an important signalling centre of the cell; its membrane is enriched in receptors and signalling molecules 
and its tightly-regulated protein composition makes it a specialized compartment within the cell, where extensive 
cross-talk between different signalling pathways takes place1,2. The protein composition within the cilium is con-
trolled by the transition zone (TZ), a distinct domain that acts as a diffusion barrier at the distal end of the basal 
body3–5 and is defined by the presence of Y-shaped electron dense structures that connect the axonemal microtu-
bule doublets and the ciliary membrane6. Two distinct protein complexes form the TZ, the NPHP module and the 
MKS module that are composed of proteins mutated mainly in nephronophthisis and Meckel-Gruber syndrome, 
respectively. Loss of function studies on the components of these complexes revealed that the TZ is essential for 
ciliogenesis and for the control of ciliary composition7. Absence of JBTS proteins from the TZ can affect ciliary 
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membrane composition with dramatic effects on ciliary enrichment of important signalling proteins such as 
smoothened (SMO) and adenylate cyclase 3 (AC3)4. It has been proposed that perturbations of TZ architecture 
cause JBTS5,8.
An important hub within the TZ protein network is CEP290, a 290 kDa centrosomal protein, which is part 
of the MKS complex but also interacts with NPHP complex components9,10. Electron microscopy studies based 
on immuno-gold labelling of cep290 in Chlamydomonas reinhardtii showed that cep290 associates with the TZ 
links and localises between the outer doublet microtubules and the membrane of the transition zone11 where 
it is thought to link these two components by binding the ciliary membrane through its N-terminus and the 
microtubules through a C-terminal domain12. CEP290 is also found associated with centriolar satellites where it 
interacts with their main component, PCM-1. Both CEP290 and PCM-1 are implicated in ciliogenesis through 
the recruitment to the primary cilium of the small GTPase, BBS complex interactor, RAB813,14.
CEP290 (JBTS5) is the most commonly mutated gene in JBTS patients with a cerebello-retinal-renal pheno-
type15,16. In the absence of a full-length CEP290 protein, JBTS cells display reduced ciliogenesis and fibroblasts 
from one patient were shown to have reduced ciliary levels of SMO and AC317.
We have recently demonstrated that antisense oligonucleotide (ASO)-mediated skipping of the mutated exon 
is able to restore CEP290 expression and rescues cilia length defects in urine derived renal epithelial cells (URECs) 
from a JBTS5 patient with homozygous mutations in CEP290 (c.5668 G > T; p.(G1890X))18.
Here we analyse the ciliary phenotype of fibroblast cells from a homozygote and a heterozygote carrier of a 
premature stop codon p.(G1890X) in CEP290 and show that cilia elongation and aberrant ciliary protein compo-
sition are typical features in JBTS5 cells. We demonstrate that ASO-mediated skipping of mutated exon 41 rescues 
not only elongated ciliary phenotypes, as previously shown in URECs18, but also ciliary composition defects, 
providing further functional evidence for the use of this therapeutic approach to treat JBTS. Importantly, skipping 
of the premature stop codon on one allele in fibroblasts from a compound heterozygote patient is sufficient to 
rescue ciliary defects.
Results
Reduced CEP290 protein levels in JBTS5 fibroblasts lead to ciliary defects. We generated fibro-
blast lines from skin biopsy specimens obtained from a JBTS5 patient (P1, referred to as JBTS-AA in our URECs 
studies)18 with a homozygous nonsense mutation c.5668 G > T; p.(G1890X) in CEP290 and an unrelated wild 
type control (C1). We also derived fibroblasts from a JBTS5 patient (P2) with compound heterozygous muta-
tions in CEP290 and from a control heterozygote (C2; patient P2 is referred to as JSRD-2, control C2 as Ctrl-4, 
respectively, in a related fibroblast study)17. P2 and C2 are both heterozygote for the c.5668 G > T allele; the other 
CEP290 allele in P2 harbours a truncating frameshift mutation (Supplementary Table S1). Indeed, c.5668 G > T; 
p.(G1890X) is a frequent mutation within CEP290, representing the 16% of all CEP290 mutations (https://cep-
290base.cmgg.be).
CEP290 wild type protein has been reported to localise at the TZ as well as at centriolar satellites11,14. 
Immunofluorescence analysis revealed that, whilst in control fibroblasts CEP290 localises mainly to the proximal 
end of the primary cilium, in patient fibroblasts, P1 and P2, no full-length CEP290 protein was detectable at the 
transition zone, or elsewhere in the cell (Fig. 1a, Supplementary Fig. S1).
A premature stop codon can result either in the production of a truncated protein or in gene knockdown, as 
the aberrant transcript may be degraded by nonsense-mediated decay. Consistently with that previously described 
in URECs18, qPCR assay shows that CEP290 transcript abundance in P1 fibroblasts was dramatically reduced to 
15% of the expression observed in wild type C1 cells. We detected a similar reduction to 18% of CEP290 tran-
script in patient P2 fibroblasts compared to wild type cells, indicating that mRNA transcripts from mutated alleles 
are unstable in these cells. CEP290 expression levels in heterozygote control C2 c.5668 G > T; p.(G1890X) were 
reduced to approximately 50% compared to wild type cells C1 (Fig. 1b).
Absence of TZ proteins leads to ciliary composition defects4. TZ abnormalities, that result in aberrant cilia 
composition, have been proposed to be at the basis of JBTS5,8. We wondered whether defects in ciliary composi-
tion are a typical feature in JBTS5 patient cells.
Defects in the transport of the ciliary protein AC3 were previously described in a single JBTS5 patient17. 
Immunofluorescence analysis revealed that loss of CEP290 protein expression results in a reduced ciliary local-
isation, but not reduced total protein levels, of the ciliary protein AC3 (Fig. 1c, Supplementary Fig. S1) in both 
P1 and P2 cell lines. Moreover, Shimada et al. recently described low levels of JBTS protein ADP Ribosylation 
Factor-Like GTPase 13B (ARL13B) in the cilium in P2 JBTS5 fibroblasts, as opposed to total protein levels, sug-
gesting incorrect trafficking of ARL13B to the cilium17. We confirmed reduced ciliary localisation of ARL13B in 
P2 fibroblasts and observed a similar reduction in P1, not accompanied by a reduction in total protein expression 
or stability, as revealed by western blot, indicating that defects in the localisation of ciliary membrane proteins to 
the cilium are a common feature in JBTS5 cells (Fig. 1d, Supplementary Fig. S1).
Electron microscopy and immunofluorescence analysis (where cilia were identified using both ARL13B and 
acetylated α-tubulin staining) revealed that CEP290 loss at the TZ also results in a reduced percentage of cells 
that display a primary cilium after serum starvation and in increased average cilia length in JBTS5 fibroblasts 
(Supplementary Fig. S2), as previously described17. It has been reported that AC3 inhibition results in increased 
ciliary elongation19, which implies that AC3 contributes directly or indirectly to the regulation of primary cilia 
length. Interestingly, treatment of patient fibroblasts P1 and P2 with adenylate cyclase (AC) allosteric agonist 
forskolin resulted in a rescue of cilia elongation (Fig. 2a,b) and biogenesis (Fig. 2a,c) but not of ciliary localisation 
of ARL13B (Fig. 2d).
ASO-induced skipping of mutated exon 41 rescues CEP290 protein expression. JBTS5 patient 
P1 is homozygous and P2 is compound heterozygous for the CEP290 mutation c.5668 G > T; p.(G1890X), located 
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within exon 41, a 123 bp exon which begins and ends in the same reading frame. Skipping of this exon would lead 
to a shorter mRNA transcript that could escape nonsense-mediated degradation leading to the production of a 
near full-length CEP290 protein. We designed a morpholino antisense oligonucleotide (ASO) that targets the 
exon 41-intron 41 boundary of human CEP290 to induce skipping of exon 41 from the transcript (Ex41 skip ASO, 
Fig. 3a), as previously described18. Treatment of control and patient fibroblast cells with 1 µM Ex41 skip ASO 
for 48 h efficiently induced skipping of exon 41 in a portion of the CEP290 transcripts, as confirmed by RT-PCR 
analysis (Fig. 3b) and Sanger sequencing following cloning in pGEM-T Easy Vector of PCR products (Fig. 3c,d). 
RT-PCR on control and patient fibroblasts treated with 5 μM Ex41 skip ASO shows undetectable levels of CEP290 
transcript retaining exon 41, indicating complete skipping of exon 41 at this dose (Supplementary Fig. S3).
To determine whether Ex41 skip ASO-induced skipping of the nonsense mutation c.5668 G > T within the 
CEP290 transcript prevents nonsense-mediated degradation, we measured the levels of CEP290 mRNA by qPCR. 
Indeed, CEP290 transcript levels in patient fibroblasts increased when cells were treated with Ex 41 skip ASO. 
In patient lines, we observed a 2-fold increase in CEP290 mRNA in compound heterozygous P2 and a 5-fold 
increase in CEP290 mRNA in homozygous P1. Interestingly, in the heterozygote control C2, carrying only a 
monoallelic change (c.5668 G > T), ASO-induced skipping of exon 41 resulted in a 2-fold increase of CEP290 
transcript levels, compared to cells treated with a standard control morpholino antisense oligonucleotide (Std 
ASO), indicating that ASO treatment rescued the expression of the heterozygous CEP290 allele (Fig. 4a).
To assess whether this increase in CEP290 transcript level was accompanied by an increase in protein and 
whether this effect was dependent on ASO concentration, we treated P2 cells with increasing concentrations of 
Ex41 skip ASO and checked CEP290 protein levels by immunoblot. It is worth noting that the antibody used 
binds to an epitope at the C-terminal of CEP290 protein, meaning that it can only recognise full-length or nearly 
full-length protein. Full-length CEP290 protein in patient line P2, which was undetectable, dramatically increased 
when cells were treated with Ex41 skip ASO. We observed an ASO dose-dependent effect when cells were treated 
with 1 μM and 5 μM Ex41 skip ASO, with no further increase in near full-length protein levels at 10 μM (Fig. 4b). 
Similarly, in patient line P1, it is possible to distinguish by immunoblot only a very faint band at 290 kDa, which 
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Figure 1. Reduced CEP290 protein expression leads to defects in localisation of ciliary membrane proteins 
AC3 and ARL13B. (a) Representatisve immunofluorescence images of control heterozygote fibroblasts C2 and 
JBTS5 fibroblasts P1 and P2, serum starved for 48 h. CEP290 protein is visible at the base of cilium in control 
fibroblasts, but is not detectable in P1 and P2. Green - CEP290, Red - ARL13B, Violet - pericentrin. Scale 
bar 5 μm. (b) CEP290 gene expression analysis of fibroblasts obtained from wild type control fibroblasts C1, 
control heterozygote fibroblasts C2 and JBTS5 fibroblasts P1 and P2, serum starved for 48 h. Expression level of 
CEP290 is reduced by more than 80% in patients fibroblasts compared to the wild type control, indicating that 
mutant transcripts are efficiently degraded. Each bar represents the mean value from three replicates. Values are 
normalised to wild type control C1. (c) Representative immunofluorescent micrographs of control wild type 
fibroblasts C1, control heterozygote fibroblasts C2 and JBTS5 fibroblasts P1 and P2, serum starved for 48 h. 
Ciliary AC3 levels are visibly reduced in JBTS5 fibroblasts. Green – AC3, Red – ARL13B, Violet – pericentrin. 
Scale bar 5 μm. (d) Representative immunofluorescence micrographs of control wild type fibroblasts C1, control 
heterozygote fibroblasts C2 and JBTS5 fibroblasts P1 and P2, serum starved for 48 h. Ciliary ARL13B levels are 
visibly reduced in JBTS5 fibroblasts. Green – ARL13B, Red – acetylated α-tubulin. Scale bar 5 μm.
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indicates a partial read-through of the nonsense mutation p.(G1890X). However, when patient fibroblasts were 
treated with 5 μM Ex41 skip ASO, CEP290 protein levels dramatically increased (Fig. 4c).
Near full-length CEP290 protein lacking exon 41 correctly localises at the TZ. In order to evaluate 
the functionality of the abundant protein produced by exon 41-skipped CEP290 transcript, we first checked by 
immunofluorescence whether it correctly localised at the base of the cilium. Serum-starved patient cells treated 
with Ex41 skip ASO displayed a detectable fluorescent intracellular signal for CEP290 that localises at the base of 
the cilium (Fig. 5a, Supplementary Fig. S4). To examine the exact localisation of CEP290 we compared it with the 
position along the ciliary axis of the MKS complex components TMEM67 and AHI1. While in untreated patient 
Figure 2. Treatment with forskolin results in a rescue of cilia biogenesis and elongation defects but not of ciliary 
localisation of ARL13B in JBTS5 cells. (a) Immunofluorescence microscopy of control fibroblast lines C1, C2 
and JBTS5 lines P1, P2. Untreated, serum starved cells (left panel) and cells treated with 25 μM forskolin (right 
panel). Treatment with forskolin results in an increase of ciliated cells upon serum starvation and in a rescue 
of ciliary phenotype in JBTS5 cells. DAPI- blue (Nuclei), Green - ARL13B, Red - Acetylated α-tubulin. Scale 
bar 20 μm. (b) Quantification of cilia length in control fibroblast lines C1, C2 and JBTS5 lines P1, P2, untreated 
or treated with forskolin. Mean length of JBTS5 fibroblast cilia decreased from 6.7 μm to 5.5 μm and 8.0 μm to 
4.8 μm in P1 and P2, respectively, after treatment with forskolin. *P < 0.05, **P < 0.01, ***P < 0.001, ns, non-
significant, one-way ANOVA, n = 341. (c) Quantification of percentage of ciliated cells in control fibroblast 
lines C1, C2 and JBTS5 lines P1, P2, untreated or treated with forskolin. Percentage of ciliated JBTS5 fibroblasts 
increased from 34% to 59% and from 45% to 71% in P1 and P2, respectively, after treatment with forskolin. 
***P < 0.001, ns, non-significant, Fisher’s exact test. Bonferroni correction was used to adjust for multiple 
comparisons, n = 1244. (d) Quantification of ciliary ARL13B intensity normalised to the background in 
control fibroblast lines C1 and JBTS5 lines P1 and P2, untreated or treated with forskolin. Values are expressed 
as ARL13B ciliary intensity relative to ciliary intensity in C1 cells. ***P < 0.001, ns, non-significant, one-way 
ANOVA, n = 239. FOR, forskolin.
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cells CEP290 signal at the centriole is absent or faint, the latter case likely due to a read-through of the mutation, 
in control and treated cells, CEP290 localises at the same position along the ciliary proximal-distal axis as TZ 
markers and JBTS proteins TMEM61 (JBTS6) and AHI1 (JBTS3, Fig. 5b,c). It is noteworthy that, consistently 
with that reported previously in JBTS5 cells17, there is no obvious defect in the localisation of other TZ proteins 
in the absence of full-length CEP290 protein, indicating that the overall TZ structure is unaltered (Fig. 5b,c). 
Similarly, localisation of PCM-1 granules in the pericentriolar region appears unaltered in JBTS5 cells, as well as 
in cells treated with Ex41 skip ASO, consistent with previous reports17 (Fig. 5d).
Near full-length CEP290 protein expression rescues ciliary defects in JBTS5 fibroblasts. Next, 
we examined whether Ex41 skip ASO induces the expression of a near full-length CEP290 protein, able to rescue 
JBTS ciliary defects, including reduced localisation of AC3 and ARL13B proteins in the ciliary membrane, elon-
gated cilia and impaired ciliogenesis.
Quantification of AC3 fluorescence signal intensity revealed that AC3 in the cilium significantly increased in 
Ex41 skip ASO-treated patient fibroblasts (Fig. 6a,b, Supplementary Fig. S5). Similarly, Ex41 skip ASO treatment 
increased ciliary localisation of ARL13B, implying that the protein product of CEP290 exon 41-skipped transcript 
is able to promote correct localisation of membrane-associated proteins to the cilium (Fig. 6c,d, Supplementary 
Fig. S5).
Hedgehog (HH) signalling defects were shown to be implicated in JBTS20,21. qPCR analysis of HH down-
stream effector GLI1 demonstrated a strong upregulation (∼14 fold) of HH pathway activation in JBTS5 cells, 
which was not fully rescued in Ex41 skip ASO treated cells (Supplementary Fig. S6).
Immunofluorescence analysis revealed that treatment of JBTS5 fibroblasts P1 and P2 with Ex41 skip ASO 
reduced cilia length to levels comparable to control cells C1 and C2 (Fig. 7a,b). Finally, ASO treatment also 
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Figure 3. Ex41 skip ASO treatment is able to induce targeted skipping of exon 41 from CEP290 transcript. 
(a) Schematic of human CEP290, consisting of 54 exons. In red, exon 41. The full-length mRNA transcript 
consists of 7951 nucleotides, translated into a protein of 2479 amino acids. JBTS5 patient fibroblasts harbour 
a nonsense mutation in the CEP290 gene (c.5668 G > T; p.(G1890X)) leading to a premature stop codon and 
truncation of the reading frame within exon 41 as shown. Mutation on the other CEP290 allele in P2 is also 
shown. A morpholino-based antisense oligonucleotide (Ex41 skip ASO) was designed to block the splice 
donor site of exon 41 to promote the skipping of exon 41. Skipping the 123 nucleotides of exon 41 leads to a 
predicted shorter mRNA transcript that encodes a protein consisting of 2438 amino acids. Arrows indicate 
forward (FOR) and reverse (REV) primers, targeting a site in exon 39 and a site in exon 42, respectively, used 
for RT-PCR. (b) RT-PCR on cDNA isolated from C2, P1 and P2 lysates demonstrates partial efficiency of 1 μM 
Ex41 skip ASO in skipping 123 bp of exon 41, leading to a shorter CEP290 mRNA transcript (corresponding to 
the 397 bp amplicon). Cells treated with 1 μM Ex41 skip ASO produce also a non-skipped CEP290 transcript 
(corresponding to the 520 bp product). In untreated cells only a non-skipped amplicon of 520 bp is detectable. 
HPRT1 was used as housekeeping gene. (c) Sanger sequencing following T-cloning of the 520 bp PCR product 
from P2 fibroblasts treated with 1 μM Ex41 skip ASO shows presence of exon 41. (d) Sanger sequencing 
following T-cloning of the 397 bp PCR product from P2 fibroblasts treated with 1 μM Ex41 skip ASO shows 
skipping of exon 41.
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partially rescued cilia biogenesis defects, leading to an increase in the percentage of JBTS5 cells that display a 
primary cilium after serum starvation (Fig. 7c, Supplementary Fig. S6).
Discussion
An array of ciliary defects characterises JBTS5 fibroblasts. Primary cilia are important signalling 
hubs in which coordination and extensive cross-talk between multiple signals from the extracellular environment 
take place. Dysfunctional primary cilia may lead to impaired signal transduction with dramatic consequences on 
tissue development and homeostasis22. In order to identify essential phenotypic end-points to predict efficacy of 
potential therapies in vivo, it is important to understand how JBTS mutations affect ciliary morphology, compo-
sition and signalling.
CEP290 is required for assembly of the primary cilium and siRNA knockdown in human cells results in a 
reduction of ciliogenesis13,14. Consistent with this, we show that JBTS5 fibroblasts, characterised by low CEP290 
expression levels, display cilium biogenesis defects. Lack of CEP290 expression in JBTS5 fibroblasts also results in 
an elongated ciliary phenotype. This phenotype is consistent with that previously reported in JBTS5 URECs18,23 
and fibroblasts17. On the other hand, URECs and fibroblasts derived from patients with Leber congenital amau-
rosis (LCA), a severe form of retinal degeneration with no renal or cerebellar manifestations, displayed detectable 
levels of full-length CEP290, normal ciliogenesis and cilia morphology17,23. Taken together, these results indicate 
that aberrant cilium biogenesis and length may be characteristic features of JBTS cells and suggest a possible link 
between expression level of CEP290, ciliary phenotype and severity of clinical presentation.
It has been demonstrated that TZ proteins are required to preserve TZ structure integrity and trafficking of 
ciliary membrane proteins, which are involved in ciliary signalling4,5,8. MEFs null for JBTS genes that belong to 
the TZ MKS complex display a reduction of ciliary enrichment of the membrane proteins AC3 and ARL13B4. 
Consistent with the gating function of TZ proteins to control ciliary membrane composition, fibroblasts from a 
single JBTS5 patient were shown to be defective in AC3 ciliary localisation17. To understand whether the defective 
ciliary localisation of AC3 is a common feature of JBTS5 fibroblasts, we investigated the localisation of AC3 to the 
cilium of fibroblasts in two different JBTS5 patients. Indeed, our results show that low expression levels of CEP290 
in JBTS5 fibroblasts lead consistently to defects in ciliary membrane composition. Similarly, we demonstrate that 
low levels of CEP290 in P1 fibroblasts result in a reduction of ARL13B ciliary localisation, as previously reported 
for P217, confirming that mislocalisation of ciliary proteins is a widespread feature in JBTS cells.
We observed a strong upregulation of HH signalling upon SAG treatment in JBTS5 cells compared to control 
cells, even though the number of cilia was lower. This observation is in line with that previously observed in 
JBTS5 cells17 and points toward the fact that CEP290 is a negative regulator of HH signalling. We hypothesise that 
Figure 4. Treatment with Ex41 skip ASO induces the expression of a near full-length CEP290 protein. (a) 
CEP290 gene expression analysis of fibroblasts obtained from control heterozygote fibroblasts C2 and JBTS5 
fibroblasts P1 and P2 treated with 5 μM Std ASO or 5 μM Ex41 skip ASO and serum starved for 48 h. In 
heterozygote control C2, ASO-induced skipping of exon 41 results in a 2-fold increase of CEP290 transcript 
levels. Similarly, treatment with Ex41 skip ASO leads to a 2-fold increase of CEP290 transcript levels in JBTS5 
fibroblasts P2 (59% of CEP290 expression levels in heterozygote C2 cells) and to a 5-fold increase in JBTS5 
fibroblasts P1 (133% of CEP290 expression levels in heterozygote C2 cells). Each bar represents mean value 
from three replicates. Values are normalised to heterozygote control C2. (b) Western blot demonstrates the 
presence of full-length CEP290 protein (290 kDa) in C2 protein lysates, whereas protein lysates from P2 cells 
treated with Std ASO show absence of full-length protein. Treatment with increasing concentrations (1 μM, 
5 μM and 10 μM) of Ex41 skip ASO for 48 h results in a rescue of CEP290 protein expression in P2 cells. 
Vinculin (124 kDa) serves as loading control. (c) P1 protein lysates treated with Std ASO show a near absence 
of full-length protein. CEP290 exon 41 skipping induced by 5 μM Ex41 skip ASO in P1 cells demonstrates the 
rescue of CEP290 protein translation to levels higher than in heterozygote C2 cells. Vinculin serves as loading 
control.
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Figure 5. Treatment with Ex41 skip ASO induces the expression of a near full-length CEP290 protein that 
localises at the TZ. (a) Immunofluorescence shows that CEP290 protein is not detectable in untreated P1 and P2 
cells. Treatment with 5 μM Ex41 skip ASO in serum-free medium for 48 h rescues CEP290 protein expression 
which localises to the base of the cilium, in P1 and P2 cells. Notably, skipping of exon 41 does not alter CEP290 
protein localisation in control lines C1 and C2. Green - CEP290, Red - ARL13B, Violet - pericentrin. Scale bar 
5 μm. (b) Immunofluorescence shows that treatment with 5 μM Ex41 skip ASO in serum-free medium for 48 h 
induces the expression of near full-length CEP290 protein that localises at the same position along the ciliary 
proximal-distal axis as the TZ component TMEM67. Green - CEP290, Violet - TMEM67, Red - ARL13B. Scale 
bar 5 μm. (c) Immunofluorescence shows that treatment with 5 μM Ex41 skip ASO in serum-free medium for 
48 h induces the expression of near full-length CEP290 protein that localises at the same position along the 
ciliary proximal-distal axis as the TZ component AHI1. Green - CEP290, Violet - AHI1, Red - ARL13B. Scale 
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decreased levels of AC3 within the cilium, due to disturbed membrane protein trafficking, may contribute to the 
observed upregulation of HH in JBTS5 fibroblasts. In fact, it has been shown that ACs regulate HH pathway in 
mouse cerebellar granular neuron precursors and in chicken embryonic neural tube, where their ciliary localisa-
tion is required to repress HH signalling24, likely through the regulation of Protein kinase A (PKA) activity at the 
cilium base. Altered ciliary trafficking following pathway activation of other HH regulators, such as GPR161 and 
SMO, in the absence of a functional CEP290, is likely as well to contribute to the observed upregulation of GLI1 
levels, as shown in fibroblasts from a different JBTS5 individual17.
Despite the observed alterations in ciliary membrane protein trafficking, which is consistent with a loss of TZ 
diffusion barrier function, the lack of full-length CEP290 protein doesn’t result in a disruption of TZ structure, 
as indicated by the normal localisation of MKS complex proteins TMEM67 and AHI1 in JBTS5 cells. The pres-
ervation of TZ structure integrity in the absence of CEP290 in patient cells is consistent with previous studies in 
human CEP290 mutant cells17 but appears to be in contrast with observations in a cep290 Caenorhabditis elegans 
mutant strain, where lack of cep290 results in an impaired assembly of the MKS module at the TZ25. These results 
may underlie a species-specific role of CEP290 that, in human cells, appears to be necessary for maintaining TZ 
diffusion barrier function but, unlike other TZ components such as TCTN2 and RPGRIP1L5, is not essential for 
TZ structural integrity.
Treatment with forskolin partially rescues the ciliary defects in JBTS5 fibroblasts. It has been 
shown that AC3 inhibition can result in aberrant ciliary elongation and that pre-treatment with forskolin can 
partly prevent elongation induced by lithium-mediated inhibition of AC319. Consistently, we show here that treat-
ment of JBTS5 fibroblasts with AC activator forskolin results in shortening of cilia to levels comparable to healthy 
controls. We therefore propose that activation of residual ciliary AC3 with forskolin may partially restore its 
function in JBTS5 fibroblasts, rescuing aberrant cilia elongation.
Indeed, modulation of cyclic AMP (cAMP) levels, the downstream product of AC3, in the treatment of renal 
ciliopathies has been widely studied with remarkable success and the V2 receptor antagonist tolvaptan is the 
only approved non-conservative treatment for the ciliopathy autosomal dominant polycystic kidney disease26. 
However, JBTS5 fibroblasts display an array of ciliary defects, some of which do not seem to be downstream of 
AC3 mislocalisation and thus cannot be rescued by its activation. ARL13B is reduced in the ciliary membrane 
of JBTS5 fibroblasts and this defect cannot be rescued by forskolin treatment, indicating that it may be a direct 
consequence of loss of CEP290 gate-keeper function at the TZ.
Targeted exon skipping restores CEP290 functions at the TZ in JBTS5 fibroblasts. As opposed to 
pharmacological interventions that target a particular aberrant pathway associated with the disease, correction of 
the primary genetic lesion represents a more efficient means to restore the full array of CEP290 functions, without 
the risk of unwanted side effects.
However, due to the large gene size, gene replacement therapies may prove challenging in the case of CEP290, 
although lentiviral transfer of CEP290 has been employed successfully in patient cells27 and administration of 
multiple AAV intein vectors improves the retinal phenotype of LCA mice by reconstituting full-length CEP290 
expression28. Another strategy that has been successfully explored in LCA models to overcome the limitations 
imposed by CEP290 large size is represented by the in trans complementation of the mutation using selected 
fragments of the gene29,30. On the other hand, mutations that affect transcript splicing would be ideal targets for 
ASO-mediated therapies, as shown in the case of the common mutation c.2991 + 1655A > G in CEP290, which 
introduces a pseudo-exon and causes LCA31–33. Importantly, a recent clinical trial has demonstrated safety and 
tolerability of intravitreal injections of ASO, to correct aberrant splicing and showed improved visual acuity in 
these patients34.
Interestingly, several studies have recently shown in retinal dystrophy patients, with nonsense mutations in 
CEP290, that mild retinal phenotypes are associated with nonsense-mediated alternative splicing or endogenous 
basal exon skipping35,36. It has been proposed that a widespread, low-level alternative splicing leads to the expres-
sion of low levels of transcripts lacking the mutated exon, which can mitigate the effects of certain mutations of 
CEP290, partially explaining the observed genetic pleiotropy37.
Indeed, qRT-PCR on fibroblast cDNA from a patient carrying a truncating mutation on exon 41 revealed high 
levels of CEP290 transcript lacking this exon, when normalised to total CEP290 transcript, compared to control 
or other patients with different mutations in CEP29037. This indicates that skipping of exon 41 occurs naturally to 
a certain extent and prevents degradation of skipped transcript.
We have recently shown that targeted skipping of the mutated exon 41 is a promising therapeutic approach 
for JBTS5, as it restores CEP290 near full-length protein expression and rescues elongated cilia in URECs from 
a JBTS5 patient homozygous for the mutation c.5668 G > T; p.(G1890X) in CEP290. Moreover, we showed that 
systemic delivery of an ASO to skip the gene-trap in a mouse model of JBTS5 leads to a rescue of elongated cilia 
and cystic phenotype in the kidney18.
Here we expand our studies to investigate at a molecular level the consequences of ASO-mediated restoration of 
CEP290 expression and show a rescue of TZ functions, whose loss has been proposed to be at the basis of JBTS5. We 
show that ASO treatment results in a restoration of gate-keeper functions of CEP290 protein in JBTS5 patient fibro-
blasts, with a rescue not only of cilia biogenesis and morphology, but also of ciliary localisation of AC3 and ARL13B. 
bar 5 μm. (d) Representative immunofluorescence micrographs of control fibroblasts C1, C2 and JBTS5 cells P1 
and P2. PCM-1 localisation at centriolar satellites is not altered in the absence of full-length CEP290. Green - 
CEP290, Violet - PCM-1, Red - ARL13B. Scale bar 5 μm.
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Moreover, by testing ASO-mediated exon skipping in fibroblasts from a compound heterozygote patient that carries a 
skippable mutation on a single allele, we show that ASO is consistently able to rescue ciliary defects in multiple patients 
and that the skipping of heterozygous allele of a compound heterozygous phenotype is sufficient to induce the rescue.
Figure 6. Treatment with Ex41 skip ASO increases ciliary localisation of membrane proteins AC3 and ARL13B 
in JBTS5 fibroblasts. (a) Representative immunofluorescence micrographs of control fibroblasts C1 and JBTS5 
cells P1 and P2, serum starved for 48 h. Treatment of JBTS5 fibroblasts with 5 μM Ex41 skip ASO for 48 h 
increases AC3 ciliary localisation in JBTS5 lines P1 and P2. Green – AC3. Scale bar 5 μm. (b) Quantification 
of ciliary AC3 intensity after background subtraction. Values are expressed as AC3 ciliary intensity relative to 
ciliary intensity in C1 cells. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA, n = 248. (c) Representative 
immunofluorescence images of control fibroblasts C1 and JBTS5 cells P1 and P2, serum starved for 48 h. 
Treatment of JBTS5 fibroblasts with 5 μM Ex41 skip ASO for 48 h increases ciliary localisation of the membrane 
protein ARL13B. Green – ARL13B. Scale bar 5 μm. (d) Quantification of ciliary ARL13B intensity normalised 
to the background. Values are expressed as ARL13B ciliary intensity relative to ciliary intensity in C1 cells. 
*P < 0.05, ***P < 0.001, one-way ANOVA, n = 281.
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Figure 7. Treatment with Ex41 skip ASO rescues cilia length and biogenesis in JBTS5 fibroblasts. (a) 
Representative immunofluorescence images of control fibroblasts C2 and JBTS5 cells P2, treated with 5 μM Std 
ASO or 5 μM Ex41 skip ASO and serum starved for 48 h. Treatment with Ex41 skip ASO results in a rescue of 
ciliary phenotype in JBTS5 cells. Green - ARL13B, Red – acetylated α-tubulin, Violet - pericentrin. Scale bar 
3 μm. (b) Quantification of cilia length in control fibroblast lines C1, C2 and JBTS5 lines P1, P2, treated with 
5 μM Std ASO or 5 μM Ex41 skip ASO. The mean cilia length measured for C1 was 5.3 μm when treated with Std 
ASO and 5.6 μm after treatment with Ex41 skip ASO. The mean cilia length measured for C2 was 5.6 μm when 
treated with Std ASO or Ex41 skip ASO. Mean length of JBTS5 fibroblasts P1 cilia decreased from 7.0 μm to a 
near-control length of 4.9 μm after treatment with Ex41 skip ASO. Similarly, JBTS5 fibroblasts P2 mean cilia length 
decreased from 7.6 μm to near-control length of 5.7 μm following treatment with Ex41 skip ASO. ***P < 0.001, 
ns, non-significant, one-way ANOVA, n = 1168, data from three independent experiments. (c) Quantification of 
percentage of ciliated cells in control fibroblast lines C1, C2 and JBTS5 lines P1, P2, treated with 5 μM Std ASO or 
5 μM Ex41 skip ASO. The percentage of ciliated cells for C1 was 98% when treated with Std ASO and 71% after 
treatment with Ex41 skip ASO. The percentage of ciliated cells measured for C2 was 98% when treated with Std 
ASO and 91% after treatment with Ex41 skip ASO. Percentage of ciliated JBTS5 fibroblasts P1 increased from 24% 
to 57% after treatment with Ex41 skip ASO. Similarly, the percentage of ciliated JBTS5 fibroblasts P2 increased 
from 30% to 69%, following treatment with Ex41 skip ASO. ***P < 0.001, ns, non-significant, Fisher’s exact test. 
Bonferroni correction was used to adjust for multiple comparisons, n = 910.
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To date, there is no definitive treatment for JBTS, despite the severity of associated symptoms, such as retinal 
degeneration and nephronophthisis, which can result in end-stage renal failure at a median age of 13 years. The 
slowly progressive renal disease leaves time in many cases for therapeutic interventions, such as ASO treatment 
targeted towards the kidney.
ASO-based therapeutic approaches to promote targeted exon skipping and restore transcript reading frame 
have been successfully tested in other genetic conditions. Eteplirsen, an ASO with a morpholino backbone, has 
recently received accelerated approval from the FDA for the treatment of Duchenne muscular dystrophy38.
Further in vivo studies on humanised mouse models will be required to better assess the consequences of 
exon skipping on renal and extra-renal tissues and precision medicine approaches are warranted to evaluate the 
suitability of exon skipping to treat patients with different mutations.
However, the functional in vitro study that we present here demonstrates the enormous potential of this strat-
egy to restore TZ functions altered in JBTS5 human cells, providing an encouraging picture for the translational 
value of this therapeutic approach.
Methods
Fibroblast culture. Following informed and written consent, skin samples were obtained from JBTS5 
patients and healthy controls. Ethical approval was given by the National Research Ethics Service Committee 
North East – Newcastle and North Tyneside 1 (08/H0906/28+5) and the National Research Ethics Service 
(NRES) Committee North East (14/NE/1076). All methods were performed in accordance with the relevant 
ethical guidelines and regulations.
Skin biopsies were stored in Ham’s F-10 complete medium (100 ml Ham’s F-10), 20 ml FCS (Seralab), 2 ml 
Penicillin/Streptomycin solution (10,000 U/ml), 1 ml GlutaMAX 100 × (Thermo Fisher), 1 ml Fungizone 
(Thermo Fisher) at 4 °C for 24 h. The following day, biopsies were washed in PBS and a 3 mm2 fragment of skin 
was cut using scalpels. After centrifugation in 2.5% Trypsin, tissues were incubated for 15 min at 37 °C and fur-
ther centrifuged for 5 min. Then trypsin was carefully removed and tissues were incubated in collagenase type IV 
solution (100 mg in 100 ml Ham’s F-10) for 90 min at 37 °C. After centrifugation, collagenase was removed and 
replaced with Ham’s F-10 complete medium and cell suspension was placed into a T25 flask and incubated at 
37 °C in 5% (v/v) CO2 in a humidified incubator.
After 48 h, medium was carefully removed and replaced with fresh medium. The medium was changed every 
three days. Once fibroblasts attained 70% confluence, the cells were washed in PBS, dissociated with TrypLE 
Express (Thermo Fisher) and transferred into 2 T75 flasks and returned to incubator.
Fibroblasts were kept in DMEM supplemented with 10% FBS (Thermo Fisher) and Penicillin/Streptomycin 
solution (10,000 U/ml, Thermo Fisher) 1:100 at 37 °C in a humidified atmosphere of 5% (v/v) CO2 and passaged 
when reaching 80% confluence.
70,000 cells were seeded on top of a 13 mm diameter glass coverslip for immunofluorescence applications, 
alternatively 600,000 cells were seeded in a T25 flask for RNA extraction, or 200,000 cells were seeded in each well 
of a 12 well plate for protein extraction.
Antisense oligonucleotide (Aso) treatments. To induce skipping of exon 41 from CEP290 transcript, 
a morpholino ASO (Ex41 skip ASO) (GeneTools LLC, USA) was designed to target the intron-exon boundary of 
human CEP290 (exon 41-intron 41, 5′-ATGTTTCTTCACATACCTTTTCTTT-3′). Ex41 skip ASO was dissolved 
in RNase-free water to make a 1 mM stock solution. A Standard control ASO (Std ASO) with no target sequence 
in the human genome (5′-CCTCTTACCTCAGTTACAATTTATA-3′) was used as a control. 24 h after seeding, 
fibroblasts were treated with 6 μM Endo-Porter (GeneTools LLC, USA) and with the indicated concentrations of 
Std ASO or Ex41 skip ASO in serum-free medium for 48 h.
Drug treatments. Where indicated, fibroblasts were treated with 25 μM forskolin (Selleckchem)/0.1% 
DMSO (Sigma-Aldrich) in serum-free medium for 48 h before analysis or with 100 nM SAG (Tocris)/0.1% 
DMSO (Sigma-Aldrich) in serum-free medium for 24 h before analysis.
Immunofluorescence imaging. Fibroblasts were fixed in ice-cold methanol for 10 min. After 30 min sat-
uration with 5% BSA in PBS, cells were incubated for 1 h at room temperature with the following primary anti-
bodies in blocking solution: rabbit anti-ARL13B (Proteintech, 17711-1-AP); mouse anti-ARL13B (Proteintech, 
66739-1-Ig); rabbit anti-CEP290 (Abcam, ab 85728); mouse anti-Pericentrin (Abcam, ab28144); rabbit 
anti-Pericentrin (Abcam, ab 4448); mouse anti-acetylated α-tubulin (Sigma, T6793); rabbit anti-AC3 (Abcam, 
ab 123803); rabbit anti-TMEM67 (Proteintech, 13975-1-AP); rabbit anti-AHI1 (Proteintech, 22045-1-AP); rab-
bit anti PCM-1 (Santa Cruz, sc-67204). Following washes in PBS, cells were incubated at room temperature 
for 1 h with the following secondary antibodies: donkey anti-rabbit Alexa Fluor 488 (Thermo Fisher); donkey 
anti-mouse Alexa Fluor 594 (Thermo Fisher); goat anti-mouse Alexa Fluor 647 (Thermo Fisher). Alternatively, 
cells were incubated overnight at 4 °C with primary rabbit antibodies directly labelled using Zenon Alexa Fluor 
rabbit IgG labelling kit (Thermo Fisher), washed with 0.1% PBS Tween and post-fixed with 4% PFA for 15 min. 
Following final washes in PBS, cells were mounted in Vectashield (Vector Laboratories Ltd, H-1200). Images and 
z-stacks were captured in a blinded fashion, using a Nikon (A1) confocal inverted microscope. Laser power was 
kept constant within each experiment for the channels used in intensity measurements. If channels were not used 
for intensity measurements, laser power was adjusted occasionally to facilitate cilia localisation.
scanning electron microscopy (seM) imaging. For SEM, samples were fixed overnight in 2% glut-
araldehyde in 0.1 M Sorenson’s phosphate buffer, dehydrated through a graded series of ethanol and then 
critical-point dried (Baltec dryer).
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They were coated with 10 nm of gold (Polaron coating unit) and viewed on a Tescan Vega LMU SEM operated 
at 8–10 kV.
Image analysis. Following capture, images were analysed using FIJI (ImageJ) software. The length of cilia 
was measured using the segmented line tool on a maximum intensity projection of a z-stack, merge of ARL13B 
and acetylated α-tubulin channels was used to identify the cilia and ARL13B was used to quantify cilia length. 
Fluorescence intensity of individual cilia was measured on a sum of slices projection of a z-stack; a region of inter-
est (ROI) was constructed around the cilia (identified with ARL13B staining or acetylated α-tubulin staining) to 
measure the mean grey value. To correct for local background intensity, the ROI was duplicated and dragged to a 
nearby region and background fluorescence intensity was measured.
Western blotting. A lysis buffer solution containing 4 M urea, 125 mM Tris pH 6.8, 4% SDS, 10% glyc-
erol, 5% β-mercaptoethanol and 0.02% bromophenol blue was used to lyse fibroblast cells. Protein samples were 
then heated to 95 °C for 5 min, spun at 16 000 rcf for 5 min and resolved by SDS-PAGE on a 4–20% gradient gel 
(Bio-Rad). Proteins were transferred to a 0.4 µm nitrocellulose membrane (Thermo Fisher). The membranes were 
blocked in TBS Tween (Tris-buffered saline, 0.1% Tween-20) containing 5% low fat milk for 1 h, then incubated 
with the following primary antibodies in blocking solution overnight at 4 °C: rabbit anti-CEP290 (Abcam, ab 
85728); rabbit anti ARL13B (Proteintech, 17711-1-AP); rabbit anti-AC3 (Abcam, ab 123803); mouse anti-β-Actin 
(Sigma, A228), rabbit anti-GAPDH (CST, 14C10), mouse anti-Vinculin (Sigma, V9131). After washing in TBST, 
membranes were incubated with fluorescently labelled secondary antibodies (LI-COR) for 90 min at room tem-
perature, washed again in TBST and visualized with an Odyssey CLx imaging system (LI-COR).
Rt-pCR and qRt-pCR. RNA was extracted from fibroblast cells after 48 h serum starvation using 
RNeasy minikit (Qiagen) according to the manufacturer’s instructions and quantified using a NanoDrop 2000 
Spectrophotometer (Thermo Fisher). 1 μg of RNA was reverse-transcribed using an Oligo-dT primer and 
SuperScript III Reverse Transcriptase (Thermo Fisher). The resulting cDNA was diluted 10-fold in nuclease-free 
water. RT-PCR, using GoTaq® DNA Polymerase (Promega) and CEP290 gene-specific primer pairs (5- 
TTTTAGAACTCCGGGCAGAA-3 and 5-TTGGCTTGCCACTTTTTACC-3), was performed to identify splice 
products following ASO treatment. Amplification of HPRT1 housekeeping gene cDNA was performed alongside.
qPCR to determine CEP290 expression was carried out using PrimeTime® Gene Expression Master Mix 
(IDT) and the PrimeTime® qPCR probe-based assay (IDT) CEP290-Hs.PT.58.2324908 (IDT) according to man-
ufacturer’s instructions on cDNA diluted 5-fold. Expression levels were normalised to the expression of house-
keeping genes HPRT1 and GAPDH.
Quantitative analysis of GLI1 expression was carried out using TaqMan probe Hs00171790_m1 (Thermo 
Fisher) and the qScript XLT one-step RT-qPCR mix (Quantabio) according to manufacturer’s instructions on 
RNA diluted 5-fold. Expression levels were normalised to the expression of housekeeping genes HPRT1 and 
GUSB.
statistics. All data are shown as the mean ± standard deviation. One-way ANOVA followed by a 
Newman-Keuls Multiple Comparison Test to correct for multiple comparisons was performed, unless otherwise 
stated. A P value of less than 0.05 was considered statistically significant.
Data Availability
The data generated and further information on the materials used in the current study are available from the 
corresponding author on request.
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